Jnana is committed to discovering and developing medicines that will make a transformative difference for patients using the first drug discovery platform dedicated to targeting the solute carrier (SLC) family of transporters. Headquartered in Boston, Massachusetts, Jnana Therapeutics Inc. was launched in 2017 with $50 million in Series A financing from investors including Polaris Partners, Avalon Ventures, Versant Ventures, AbbVie Ventures and Pfizer R&D Innovate.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
12/15/17	$50,000,000	Series A	AbbVie Biotech Ventures Avalon Ventures Pfizer Venture Investments Polaris Partners Versant Ventures	undisclosed
11/15/22	$107,000,000	Series C	Avalon Ventures Bain Capital Life Sciences Pfizer Venture Investments Polaris Partners RA Capital Management Versant Ventures	undisclosed